Skip to main content
. 2018 Jan 25;3(2):e96029. doi: 10.1172/jci.insight.96029

Figure 4. Optical coherence tomography (OCT) follow-up of AAV2-7m8-CMV-GFP– and PR1.7-GFP–treated eyes.

Figure 4

(A) Foveal OCT images of CMV-treated eyes (n = 2). (B) Foveal OCT images of PR1.7-treated eyes (n = 2). D0, day of injection, predose; M1.5, -2, -3, month 1.5, 2, or 3 after dose; AAV, adeno-associated virus; CMV, cytomegalovirus promoter; PR1.7, promoter of 1.7 kilobases in length, based on the human red opsin gene enhancer and promoter sequences.